Baird R W cut shares of Leap Therapeutics (NASDAQ:LPTX – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday,Zacks.com reports. Several other analysts also recently weighed in on LPTX. HC Wainwright downgraded Leap Therapeutics from a “buy” rating to a “neutral” rating in a research note on […]

Robert W. Baird cut shares of Leap Therapeutics (NASDAQ:LPTX – Free Report) from an outperform rating to a neutral rating in a report released on Wednesday morning, MarketBeat reports. The firm currently has $1.25 price target on the stock, down from their prior price target of $9.00. Separately, HC Wainwright reissued a “buy” rating and […]